Enanta Pharmaceuticals (ENTA) shares soared 5.3% in the last trading session to close at $15.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investors are always looking for stocks that are poised to beat at earnings season and Enanta Pharmaceuticals, Inc. ENTA may be one such company. The firm has earnings coming up pretty soon, and ...

Enanta Pharmaceuticals faces challenges due to lack of profitability and sales growth, as well as unwise R&D investments. The company's royalty structures are attractive but do not mitigate downside ...

In this article we will check out the progression of hedge fund sentiment towards Enanta Pharmaceuticals Inc (NASDAQ:ENTA) and determine whether it is a good investment right now. We at Insider Monkey ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

Shares of Enanta Pharmaceuticals (ENTA) have gained 5.1% over the past four weeks to close the last trading session at $5.18, but there could still be a solid upside left in the stock if short-term ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...